Japanese Tax Authorities Eye New Pharma Targets; Takeda Seeks To Resolve Double Taxation On Prevacid
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japanese tax authorities increasingly are looking at management costs during transfer-pricing investigations of pharmaceutical companies, shifting away from a focus on overseas R&D costs